Melissa Tosca - Kiora Pharmaceuticals Ex Fin
| KPRX Stock | USD 3.37 0.06 1.81% |
Insider
Melissa Tosca is Ex Fin of Kiora Pharmaceuticals
| Address | 332 Encinitas Boulevard, Encinitas, CA, United States, 92024 |
| Phone | 858 224 9600 |
| Web | https://www.kiorapharma.com |
Latest Insider Transactions
Melissa Tosca Latest Insider Activity
Tracking and analyzing the buying and selling activities of Melissa Tosca against Kiora Pharmaceuticals stock is an integral part of due diligence when investing in Kiora Pharmaceuticals. Melissa Tosca insider activity provides valuable insight into whether Kiora Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Kiora Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Kiora Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Melissa Tosca over three months ago Acquisition by Melissa Tosca of 2000 shares of Kiora Pharmaceuticals at 3.21 subject to Rule 16b-3 | ||
Melissa Tosca over three months ago Acquisition by Melissa Tosca of 2000 shares of Kiora Pharmaceuticals at 3.21 subject to Rule 16b-3 |
Kiora Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.1296 % which means that it generated a profit of $0.1296 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1369 %, meaning that it created $0.1369 on every $100 dollars invested by stockholders. Kiora Pharmaceuticals' management efficiency ratios could be used to measure how well Kiora Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -2.68 in 2024. Return On Capital Employed is likely to rise to -0.99 in 2024. At this time, Kiora Pharmaceuticals' Other Current Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 5.6 M in 2024, whereas Total Assets are likely to drop slightly above 11.7 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Sharon McBrayer | Palisade Bio | N/A | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 62 | |
| Steen Knudsen | Allarity Therapeutics | 63 | |
| Chester III | Revelation Biosciences | 44 | |
| Annie Rasmussen | Allarity Therapeutics | 67 | |
| James Foster | Virax Biolabs Group | 39 | |
| Carol Odle | Revelation Biosciences | N/A | |
| Jason Davis | Virax Biolabs Group | 52 | |
| John CPA | Unicycive Therapeutics | 62 | |
| Meeshanthini Dogan | Cardio Diagnostics Holdings | 35 | |
| Joan Brown | Allarity Therapeutics | 70 | |
| Claus Pedersen | Allarity Therapeutics | 52 | |
| MPA MD | Unicycive Therapeutics | 51 | |
| Professor MD | Allarity Therapeutics | 67 | |
| Timur Dogan | Cardio Diagnostics Holdings | 36 | |
| James JD | Allarity Therapeutics | 55 | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 60 | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
| James Rolke | Revelation Biosciences | 55 | |
| Tomasz George | Virax Biolabs Group | 40 | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 55 | |
Management Performance
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.13 |
Kiora Pharmaceuticals Leadership Team
Elected by the shareholders, the Kiora Pharmaceuticals' board of directors comprises two types of representatives: Kiora Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kiora. The board's role is to monitor Kiora Pharmaceuticals' management team and ensure that shareholders' interests are well served. Kiora Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kiora Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, Chief Officer | ||
| Brian Strem, CEO and President | ||
| Melissa Tosca, Ex Fin | ||
| Stefan Sperl, Executive Operations | ||
| MaryJane Rafii, Consultant | ||
| Melissa CPA, Executive Finance |
Kiora Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kiora Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.20 % | ||||
| Operating Margin | (121.23) % | ||||
| Current Valuation | (18.85 M) | ||||
| Shares Outstanding | 2.97 M | ||||
| Shares Owned By Insiders | 2.30 % | ||||
| Shares Owned By Institutions | 48.34 % | ||||
| Number Of Shares Shorted | 46.67 K | ||||
| Price To Book | 0.34 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Kiora Stock Analysis
When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.